KinDex Pharmaceuticals

OverviewSuggest Edit

KinDex was established to focus on the discovery and development of molecules that improve women’s health and impact chronic disease. KinDex Pharmaceuticals is developing therapeutics that work through the Bitter Taste Receptors (TAS2Rs), a family of GPCR receptors that target inflammation and metabolic dysfunction. TAS2Rs are found in multiple tissue types and regulate hormones that play a key role in chronic disease such as Polycystic Ovary Syndrome (PCOS), obesity, NASH and diabetes. Our lead candidate, KDT501, is an orally dosed, small molecule modulator of TAS2Rs that has been demonstrated safe and effective in Phase 1 and 2 clinical trials. Our next goal is to study the effects of KDT501 in patients with PCOS. PCOS is a common endocrine disorder affecting between 5 and 10 % of women of reproductive age1. Many PCOS patients have a family history of diabetes or insulin resistance or a close relative who is similarly affected by androgen excess. Irregular ovulation in combination with excess androgens, excess hair growth (hirsutism), acne and obesity can all occur in women with PCOS. Women with PCOS are at greater risk for type 2 diabetes and cardiovascular disease and possibly hypertension and abnormal lipid levels.
HQSeattle, US


KinDex Pharmaceuticals is headquartered in
Seattle, United States

Location Map

Latest Updates

Employees (est.) (Jan 2020)3

Key People/Management at KinDex Pharmaceuticals

Michael Higgins

Michael Higgins

Chief Executive Officer
Jeffrey Bland

Jeffrey Bland

President and CEO
Paul Rogers

Paul Rogers

Chief Business Officer
Neile Grayson

Neile Grayson

Vice President, Drug Development
Show more

KinDex Pharmaceuticals Office Locations

KinDex Pharmaceuticals has offices in Seattle and Boston
Seattle, US (HQ)
Seafirst Fifth Avenue Plaza, 800 5th Ave Suite 4100
Boston, US
265 Franklin St #1702
Show all (2)

KinDex Pharmaceuticals Financials and Metrics

Summary Metrics

Founding Date


KinDex Pharmaceuticals total Funding

$5.8 m

KinDex Pharmaceuticals latest funding size

$327.27 k

Time since last funding

3 years ago
KinDex Pharmaceuticals's latest funding round in August 2016 was reported to be $327.3 k. In total, KinDex Pharmaceuticals has raised $5.8 m
Show all financial metrics

KinDex Pharmaceuticals Online and Social Media Presence

Embed Graph

KinDex Pharmaceuticals Frequently Asked Questions

  • When was KinDex Pharmaceuticals founded?

    KinDex Pharmaceuticals was founded in 2009.

  • Who are KinDex Pharmaceuticals key executives?

    KinDex Pharmaceuticals's key executives are Michael Higgins, Jeffrey Bland and Paul Rogers.

  • How many employees does KinDex Pharmaceuticals have?

    KinDex Pharmaceuticals has 3 employees.

  • Who are KinDex Pharmaceuticals competitors?

    Competitors of KinDex Pharmaceuticals include Vedanta Biosciences, Therapeutic Solutions International and Valneva.

  • Where is KinDex Pharmaceuticals headquarters?

    KinDex Pharmaceuticals headquarters is located at Seafirst Fifth Avenue Plaza, 800 5th Ave Suite 4100, Seattle.

  • Where are KinDex Pharmaceuticals offices?

    KinDex Pharmaceuticals has offices in Seattle and Boston.

  • How many offices does KinDex Pharmaceuticals have?

    KinDex Pharmaceuticals has 2 offices.